Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11099088 | PMC |
| http://dx.doi.org/10.5468/ogs.24074 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Menopause Decoded: What's Happening and How to Manage It.
J Prim Care Community Health
December 2024
Mayo Clinic, Rochester, MN, USA.
Menopause marks a significant transition in a woman's life, typically occurring between the ages of 46 and 55 years, characterized by the cessation of menstruation and a decline in ovarian function. This article provides a comprehensive overview of menopause, examining its physiological, psychological, and social dimensions. It explores the hormonal changes, including decreased levels of estrogen and progesterone, and how these changes contribute to common symptoms such as hot flashes, sleep disturbances, and mood fluctuations.
View Article and Find Full Text PDFA Recent Update on the Role of Estrogen and Progesterone in Alzheimer's Disease.
Cell Biochem Funct
December 2024
Department of Biochemistry, Amala Institute of Medical Sciences, Thrissur, Kerala, India.
Alzheimer's disease (AD), one of the most prevalent neurodegenerative disease responsible for 60%-80% dementia cases globally. The disease is more prevalent among elder females. Female reproductive hormones are found to be essential for cellular activities in brain.
View Article and Find Full Text PDFHormone-induced thrombosis is mediated through non-canonical fibrin(ogen) aggregation and a novel estrogen target in zebrafish.
bioRxiv
November 2024
Department of Pediatrics, University of Michigan, Ann Arbor, MI.
Venous thrombosis is a well-known complication of sex hormone therapy, with onset typically within weeks to months after initiation. Worldwide, more than 100 million pre-menopausal women use combined oral contraceptives, with tens to hundreds of thousands developing thrombosis annually, resulting in significant morbidity and mortality. Although it is known that estrogens can alter expression of coagulation factors, the pathways and mechanisms that connect the two systems, as well as the proteins involved in progression to thrombosis, are poorly understood.
View Article and Find Full Text PDFContemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial.
BMJ
November 2024
Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden
Objective: To assess the effect of contemporary menopausal hormone therapy on the risk of cardiovascular disease according to the route of administration and combination of hormones.
Design: Nationwide register based emulated target trial.
Setting: Swedish national registries.
Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study.
PLoS Med
November 2024
Department of Radiology, Mayo Clinic, Rochester, Minnesota, United States of America.
Background: Findings from Kronos Early Estrogen Prevention Study (KEEPS)-Cog trial suggested no cognitive benefit or harm after 48 months of menopausal hormone therapy (mHT) initiated within 3 years of final menstrual period. To clarify the long-term effects of mHT initiated in early postmenopause, the observational KEEPS Continuation Study reevaluated cognition, mood, and neuroimaging effects in participants enrolled in the KEEPS-Cog and its parent study the KEEPS approximately 10 years after trial completion. We hypothesized that women randomized to transdermal estradiol (tE2) during early postmenopause would show cognitive benefits, while oral conjugated equine estrogens (oCEE) would show no effect, compared to placebo over the 10 years following randomization in the KEEPS trial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!